Special Poster Feature: Certolizumab Pegol: A Future Treatment Option for Patients Suffering from Psoriasis-Reference-Cited by-同舟云学术

Special Poster Feature: Certolizumab Pegol: A Future Treatment Option for Patients Suffering from Psoriasis

Published:2017-11-02 Issue: Volume: Page:64-65
ISSN:2054-6211
Container-title:EMJ Dermatology
language:
Short-container-title:EMJ Dermatol

Author:

Khetrapal Afsaneh¹

Affiliation:

1. ApotheCom, London, UK

Abstract

Psoriasis is a chronic inflammatory disease that is associated with a reduction in quality of life (QoL) and professional work productivity.1-3 Clinical data presented at the 26th European Academy of Dermatology and Venereology (EADV) congress regarding certolizumab pegol (CZP), an Fc-free pegylated anti-tumour necrosis factor (TNF) antibody, demonstrated a clinically meaningful and sustained psoriasis treatment effect associated with maintained improvements in QoL and work productivity.4-7

Publisher

European Medical Group

Subject

General Medicine

Reference14 articles.

1. Armstrong AW et al. Quality of life and work productivity impairment among psoriasis patients: Findings from the National Psoriasis Foundation survey data 2003-2011. PLoS One. 2012;7(12):e52935.

2. Gelfand JM et al. Determinants of quality of life in patients with psoriasis: A study from the US population. J Am Acad Dermatol. 2004;51(5):704-8.

3. Revicki DA et al. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology. 2008;216(3): 260-70.

4. Reich K et al. Maintenance of response with certolizumab pegol for the treatment of chronic plaque psoriasis: 48-week results from two ongoing Phase 3, multicenter, randomized, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). EADV P1973. EADV Congress, 13-17 September, 2017w.

5. Thaçi D et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: DLQI and WPAI patient-reported outcomes from two ongoing Phase 3, multicenter, randomized,placebo controlled studies (CIMPASI-1 and CIMPASI-2). EADV P1971. EADV Congress, 13-17 September, 2017.